Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ABBVIE INC. |
Market Closed -
Other stock markets
|
|
Pre-market 09:02:09 am | ||
| 143.41 USD | +0.72% | 142.83 | -0.40% | |
| Dec. 01 | Raymond James Adjusts Price Target on AbbVie to $181 From $177, Maintains Outperform Rating | MT |
| Dec. 01 | Will Powell deliver an early Christmas present? |  |
Valuation
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 138 674 | 130 935 | 189 171 | 239 371 | 285 707 | 253 196 | - | - |
| Enterprise Value (EV) 1 | 170 923 | 157 739 | 266 778 | 306 225 | 339 749 | 298 297 | 292 397 | 284 014 |
| P/E ratio | 25,2x | 16,8x | 39,4x | 21,0x | 24,4x | 27,2x | 21,9x | 19,3x |
| Yield | 4,28% | 4,96% | 4,52% | 3,92% | 3,53% | 4,13% | 4,31% | 4,47% |
| Capitalization / Revenue | 4,24x | 3,94x | 4,13x | 4,27x | 4,92x | 4,69x | 4,75x | 4,51x |
| EV / Revenue | 5,22x | 4,74x | 5,83x | 5,46x | 5,85x | 5,53x | 5,49x | 5,06x |
| EV / EBITDA | 10,4x | 8,89x | 11,8x | 10,6x | 11,0x | 11,5x | 11,3x | 10,1x |
| EV / FCF | 13,4x | 12,4x | 15,9x | 13,9x | 14,0x | 15,4x | 14,2x | 12,8x |
| FCF Yield | 7,48% | 8,10% | 6,29% | 7,18% | 7,14% | 6,49% | 7,02% | 7,83% |
| Price to Book | -16,9x | -16,1x | 13,7x | 15,5x | 16,6x | 18,5x | 19,6x | 18,4x |
| Nbr of stocks (in thousands) | 1 504 216 | 1 478 821 | 1 765 474 | 1 767 880 | 1 767 880 | 1 765 537 | - | - |
| Reference price 2 | 92,2 | 88,5 | 107 | 135 | 162 | 143 | 143 | 143 |
| Announcement Date | 01/25/19 | 02/07/20 | 02/03/21 | 02/02/22 | 02/09/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 32 733 | 33 266 | 45 784 | 56 122 | 58 054 | 53 943 | 53 257 | 56 151 |
| EBITDA 1 | 16 358 | 17 747 | 22 642 | 29 018 | 30 961 | 25 974 | 25 931 | 28 122 |
| EBIT 1 | 14 593 | 15 730 | 21 976 | 28 215 | 30 183 | 25 112 | 24 932 | 27 085 |
| Operating Margin | 44,6% | 47,3% | 48,0% | 50,3% | 52,0% | 46,6% | 46,8% | 48,2% |
| Earnings before Tax (EBT) 1 | 5 197 | 8 426 | 3 398 | 12 989 | 13 477 | 9 047 | 14 877 | 15 738 |
| Net income 1 | 5 687 | 7 882 | 4 616 | 11 542 | 11 836 | 8 609 | 10 863 | 11 935 |
| Net margin | 17,4% | 23,7% | 10,1% | 20,6% | 20,4% | 16,0% | 20,4% | 21,3% |
| EPS 2 | 3,66 | 5,28 | 2,72 | 6,45 | 6,63 | 5,28 | 6,54 | 7,43 |
| Free Cash Flow 1 | 12 789 | 12 772 | 16 790 | 21 990 | 24 248 | 19 359 | 20 540 | 22 237 |
| FCF margin | 39,1% | 38,4% | 36,7% | 39,2% | 41,8% | 35,9% | 38,6% | 39,6% |
| FCF Conversion (EBITDA) | 78,2% | 72,0% | 74,2% | 75,8% | 78,3% | 74,5% | 79,2% | 79,1% |
| FCF Conversion (Net income) | 225% | 162% | 364% | 191% | 205% | 225% | 189% | 186% |
| Dividend per Share 2 | 3,95 | 4,39 | 4,84 | 5,31 | 5,71 | 5,92 | 6,18 | 6,41 |
| Announcement Date | 01/25/19 | 02/07/20 | 02/03/21 | 02/02/22 | 02/09/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period : December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13 959 | 14 342 | 14 886 | 13 538 | 14 583 | 14 812 | 15 121 | 12 225 | 13 865 | 13 927 | 13 966 | 11 970 | 13 362 | 13 693 | 13 710 |
| EBITDA 1 | 7 145 | 7 559 | 7 506 | 7 156 | 7 643 | 8 090 | 8 072 | 5 682 | 6 710 | 6 706 | 6 810 | 5 449 | 6 527 | 6 684 | 6 849 |
| EBIT 1 | 6 944 | 7 336 | 7 333 | 6 958 | 7 440 | 7 909 | 7 876 | 5 503 | 6 520 | 6 510 | 6 583 | 5 509 | 6 342 | 6 509 | 6 797 |
| Operating Margin | 49,7% | 51,2% | 49,3% | 51,4% | 51,0% | 53,4% | 52,1% | 45,0% | 47,0% | 46,7% | 47,1% | 46,0% | 47,5% | 47,5% | 49,6% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | 475 | 2 610 | 1 953 | 3 997 | - | - | - | - |
| Net income 1 | 766 | 3 179 | 4 044 | 4 490 | 924 | 3 949 | 2 473 | 239 | 2 024 | 1 778 | 2 595 | 1 138 | 1 692 | 1 783 | 2 059 |
| Net margin | 5,49% | 22,2% | 27,2% | 33,2% | 6,34% | 26,7% | 16,4% | 1,96% | 14,6% | 12,8% | 18,6% | 9,51% | 12,7% | 13,0% | 15,0% |
| EPS 2 | 0,42 | 1,78 | 2,26 | 2,51 | 0,51 | 2,21 | 1,38 | 0,13 | 1,14 | 1,00 | 1,73 | 0,63 | 0,95 | 1,00 | 1,16 |
| Dividend per Share 2 | 1,30 | 1,30 | 1,41 | 1,41 | 1,41 | 1,41 | 1,48 | 1,48 | 1,48 | 1,48 | 1,52 | 1,55 | 1,55 | 1,55 | 1,55 |
| Announcement Date | 07/30/21 | 10/29/21 | 02/02/22 | 04/29/22 | 07/29/22 | 10/28/22 | 02/09/23 | 04/27/23 | 07/27/23 | 10/27/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 32 249 | 26 804 | 77 607 | 66 854 | 54 042 | 45 102 | 39 202 | 30 818 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1,97x | 1,51x | 3,43x | 2,30x | 1,75x | 1,74x | 1,51x | 1,10x |
| Free Cash Flow 1 | 12 789 | 12 772 | 16 790 | 21 990 | 24 248 | 19 359 | 20 540 | 22 237 |
| ROE (net income / shareholders' equity) | 523% | -160% | 188% | 159% | 151% | 128% | 129% | 140% |
| Shareholders' equity 1 | 1 088 | -4 915 | 2 452 | 7 243 | 7 858 | 6 751 | 8 450 | 8 546 |
| ROA (Net income/ Total Assets) | 8,74% | 10,6% | 3,85% | 15,3% | 17,2% | 9,75% | 11,0% | 12,6% |
| Assets 1 | 65 069 | 74 234 | 119 840 | 75 543 | 68 651 | 88 301 | 98 613 | 94 552 |
| Book Value Per Share 2 | -5,46 | -5,51 | 7,83 | 8,71 | 9,74 | 7,75 | 7,32 | 7,77 |
| Cash Flow per Share 2 | 8,68 | 8,98 | 10,5 | 12,8 | 14,0 | 12,2 | 11,0 | 12,8 |
| Capex 1 | 638 | 552 | 798 | 787 | 695 | 786 | 819 | 848 |
| Capex / Sales | 1,95% | 1,66% | 1,74% | 1,40% | 1,20% | 1,46% | 1,54% | 1,51% |
| Announcement Date | 01/25/19 | 02/07/20 | 02/03/21 | 02/02/22 | 02/09/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
143.41USD
Average target price
167.35USD
Spread / Average Target
+16.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.26% | 253 B $ | |
| +59.64% | 525 B $ | |
| -10.34% | 381 B $ | |
| -6.75% | 262 B $ | |
| -16.30% | 221 B $ | |
| +2.91% | 202 B $ | |
| -9.32% | 200 B $ | |
| -43.58% | 163 B $ | |
| +3.74% | 146 B $ | |
| -4.35% | 117 B $ |
- Stock
- Equities
- Stock AbbVie Inc. - Nyse
- Financials AbbVie Inc.
